Efficacy of peritoneal oxygenation using a novel artificial oxygen carrier (TRM-645) in a rat respiratory insufficiency model

Matsutani, Noriyuki; Takase, Bonpei; Nogami, Yashiro; Ozeki, Yuichi; Kaneda, Shinichi; Maehara, Tadaaki; Kikuchi, Makoto

doi:10.1007/s00595-009-4104-8

Cited by 8 publications

(12 citation statements)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We performed a controlled laboratory study to test the therapeutic benefit of an intraperitoneal infusion of oxygen microbubbles in rats experiencing acute lung injury. Right pneumothorax was chosen as an appropriate model for acute lung injury based on prior work reported in the literature [20]. Two treatments were applied: oxygen microbubbles or oxygenated saline control.…”

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

“…No additional blinding was done in the study. The number of animals used in this study was determined from work by Matsutani et al [20] and a preliminary feasibility study. In Matsutani, a synthetic oxygen carrier was injected into the intraperitoneal (IP) space of rats for the purpose of systemic oxygenation.…”

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

“…In Matsutani, a synthetic oxygen carrier was injected into the intraperitoneal (IP) space of rats for the purpose of systemic oxygenation. The mean standard deviation and mean effective size were 6.9 and 19.9, respectively [20]. We assumed the same standard deviation, but half the effective size (m À m 0 ¼ 10).…”

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

“…Prior peritoneal oxygenation studies introducing aqueous perfusates, such as perfluorocarbons (PFCs) and red blood cells (RBCs), into the intraperitoneal space have reported no effect or only a mild increase in PaO 2 [15e20]. Prior to our study, the most successful application of peritoneal oxygenation used liposomal synthetic hemoglobin carrier TRM-645, which produced a mean increase in rat cardiac arrest time following a right pneumothorax from 9 to 33 min [20].…”

Section: Introductionmentioning

confidence: 95%

See 3 more Smart Citations

Systemic oxygen delivery by peritoneal perfusion of oxygen microbubbles

et al. 2014

View full text Add to dashboard Cite

Severe hypoxemia refractory to pulmonary mechanical ventilation remains life-threatening in critically ill patients. Peritoneal ventilation has long been desired for extrapulmonary oxygenation owing to easy access of the peritoneal cavity for catheterization and the relative safety compared to an extracorporeal circuit. Unfortunately, prior attempts involving direct oxygen ventilation or aqueous perfusates of fluorocarbons or hemoglobin carriers have failed, leading many researchers to abandon the method. We attribute these prior failures to limited mass transfer of oxygen to the peritoneum and have designed an oxygen formulation that overcomes this limitation. Using phospholipid-coated oxygen microbubbles (OMBs), we demonstrate 100% survival for rats experiencing acute lung trauma to at least 2 h. In contrast, all untreated rats and rats treated with peritoneal oxygenated saline died within 30 min. For rats treated with OMBs, hemoglobin saturation and heart rate were at normal levels over the 2-h timeframe. Peritoneal oxygenation with OMBs was therefore shown to be safe and effective, and the method requires less equipment and technical expertise than initiating and maintaining an extracorporeal circuit. Further translation of peritoneal oxygenation with OMBs may provide therapy for acute respiratory distress syndrome arising from trauma, sepsis, pneumonia, aspiration, burns and other pulmonary diseases.

show abstract

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

Section: Right Pneumothorax Lung Injury Modelmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Systemic oxygen delivery by peritoneal perfusion of oxygen microbubbles

et al. 2014

View full text Add to dashboard Cite

show abstract

“…hyperbaric oxygen therapy [7], pure oxygen or carbogen breathing, ozone therapy [8], hydrogen peroxide injections [9] and administration of suspensions of oxygen carrier liquids [10]. To date, however, these approaches have delivered limited success owing to lack of proven efficacy and/or unwanted side effects [11].…”

Section: Introductionmentioning

confidence: 99%

Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles

et al. 2016

View full text Add to dashboard Cite

Hypoxia has been shown to be a key factor inhibiting the successful treatment of solid tumours. Existing strategies for reducing hypoxia, however, have shown limited efficacy and/or adverse side effects. The aim of this study was to investigate the potential for reducing tumour hypoxia using an orally delivered suspension of surfactant-stabilised oxygen nanobubbles. Experiments were carried out in a mouse xenograft tumour model for human pancreatic cancer (BxPc-3 cells in male SCID mice). A single dose of 100 μL of oxygen saturated water, oxygen nanobubbles or argon nanobubbles was administered via gavage. Animals were sacrificed 30 minutes post-treatment (3 per group) and expression of hypoxia-inducible-factor-1α (HIF1α) protein measured by real time quantitative polymerase chain reaction and Western blot analysis of the excised tumour tissue. Neither the oxygen saturated water nor argon nanobubbles produced a statistically significant change in HIF1α expression at the transcriptional level. In contrast, a reduction of 75% and 25% in the transcriptional and translational expression of HIF1α respectively (p<0.001) was found for the animals receiving the oxygen nanobubbles. This magnitude of reduction has been shown in previous studies to be commensurate with an improvement in outcome with both radiation and drug-based treatments. In addition, there was a significant reduction in the expression of vascular endothelial growth factor (VEGF) in this group and corresponding increase in the expression of arrest-defective protein 1 homolog A (ARD1A).

show abstract